monday.com (MNDY) Q1 2025 Earnings Call May 12, 2025 08:30 AM ET Speaker0 Good day. My name is Janice and I'll be your conference operator today. At this time, I would like to welcome everyone to monday.com's First Quarter Fiscal Year 20 20 5 Earnings Conference Call. I would like to turn the call over to monday.com's Vice President of Investor Relations, Mr. Byron Steven. Please go ahead. Speaker1 Hello, everyone, and thank you for joining us on today's conference call to discuss the financial results for ...

Sally Beauty Holdings (SBH) Q2 2025 Earnings Call May 12, 2025 08:30 AM ET Speaker0 Good morning, everyone, and welcome to Sally Beauty Holdings' Call to discuss the Company's Second Quarter Fiscal twenty twenty five Results. All participants have been placed in a listen only mode. After management's prepared remarks, there will be a question and answer session. Additional instructions will be given at that time. Now I'd like to turn the call over to Jeff Harkins, Vice President of Investor Relations and Tr ...

Surgery Partners (SGRY) Q1 2025 Earnings Call May 12, 2025 08:30 AM ET Speaker0 Greetings, and welcome to Surgery Partners First Quarter twenty twenty five Earnings Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Dave Dougherty, CFO. Thank you. You may begin. Speaker1 Good morning, and thank you for joining Surgery Partners' first ...

Financial Data and Key Metrics Changes - For Q1 2025, total revenue was $62.5 million, up 24% from $50.3 million in Q1 2024 [5] - Net product sales of Lupkinus were $60 million, up 25% from $48.1 million in the same period of 2024 [5] - Cash flow generated from operations was $1.3 million compared to a negative $18.6 million in Q1 2024; excluding restructuring payments, cash flow was $12.4 million [5][6] - Net income was $23.3 million or $0.17 per share, compared to a net loss of $10.7 million or $0.07 per share in Q1 2024 [10] Business Line Data and Key Metrics Changes - The increase in net product sales of Lupkinus was primarily due to a rise in the number of cartons sold to specialty pharmacies and greater penetration in lupus nephritis treatment [5] - Cost of revenue for Q1 2025 was $8.6 million, up from $7.8 million in Q1 2024, while gross margin improved to 86% from 85% [9] Market Data and Key Metrics Changes - The company has seen improvements in rheumatology prescribing, indicating early diagnosis and treatment trends [16] - The American College of Rheumatology updated guidelines recommending the incorporation of drugs like Lupkinus into first-line therapy, which is expected to drive further growth [6] Company Strategy and Development Direction - The company is focused on commercial execution and operational efficiency, aiming for continued growth in Lupkinus sales and advancing the AUR 200 clinical program [6][11] - Total revenue guidance for 2025 is maintained in the range of $250 million to $260 million, with net product sales guidance of $240 million to $250 million [6][7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory for Lupkinus, citing historical performance patterns and ongoing improvements in patient treatment initiation [15][16] - The company is closely monitoring potential impacts from new federal government policies and tariffs, with minimal expected impact on operations due to existing stockpiles in the U.S. [29][30] Other Important Information - The company repurchased $5.8 million of its common shares in Q1 2025, part of a broader share repurchase program [6][9] - The company is on track to report initial results from the Phase 1 study of AUR 200 later in the quarter [7] Q&A Session Summary Question: Can you discuss the quarterly cadence for Lupkinus sales and what is driving sales? - Management indicated that sales are driven by a combination of new patient additions and persistency, with historical patterns suggesting a rise in sales in the latter half of the year [15] Question: What are the expectations for the second quarter compared to the first? - Management clarified that Q1 is not typically the lowest quarter, with historical trends indicating a soft summer followed by a rise in Q4 [21][22] Question: Can you elaborate on the ANDA filers challenging the dosing protocol patent? - The company is actively defending its patents and has filed infringement lawsuits against ANDA filers, with ongoing litigation expected [24] Question: What is the company's exposure to potential tariffs and government reimbursement policies? - The company has several years of product stockpiled in the U.S. and does not anticipate significant impact from tariffs on overall costs [29][30] Question: What endpoints are expected to differentiate AUR 200 from other inhibitors? - The Phase 1 results will provide insights into pharmacokinetics and pharmacodynamics, which will help assess AUR 200's competitive profile [60]

Financial Data and Key Metrics Changes - SelectQuote reported consolidated revenues of $408 million for Q3 2025, an 8% increase compared to the previous year [4][21] - Consolidated EBITDA for the quarter was $38 million, reflecting a margin of 9% despite a mix shift towards lower-margin Healthcare Services [5][21] - The trailing twelve-month revenue to customer acquisition cost (CAC) ratio improved to 5.8x from 4.2x a year ago, indicating enhanced marketing efficiency [9][10] Business Line Data and Key Metrics Changes - The Senior segment generated $169 million in revenue with an adjusted EBITDA of $46 million, achieving a margin of 27% despite a 26% reduction in agent headcount [22][24] - Healthcare Services revenue grew 53% year-over-year to $190 million, with adjusted EBITDA of $6 million [27] - Life Insurance revenues increased by 13% to $46 million, with adjusted EBITDA more than doubling to $6 million, resulting in a margin of 14% [29] Market Data and Key Metrics Changes - SelectQuote's SelectRx business saw membership grow to 106,000, a 41% increase year-over-year, contributing to significant revenue growth [4][27] - The company noted a favorable final rate notice for the 2026 plan year, which is expected to alleviate pressures in the Medicare Advantage market [7][58] Company Strategy and Development Direction - The company aims to enhance profitability in its Healthcare Services segment by refining membership parameters and focusing on efficiency [15][51] - SelectQuote plans to leverage its scale and improve margin consistency, even if it results in slower membership growth in the near term [16][51] - The company is committed to maintaining high integrity and compliance in the Medicare Advantage industry amid ongoing legal challenges [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate the Medicare Advantage landscape, citing improved agent efficiency and customer attachment rates [36][38] - The company anticipates potential headwinds in Q4 due to new beneficiary eligibility parameters and the ramp-up of its Kansas distribution facility [30][62] - Management remains optimistic about the long-term growth prospects of the Healthcare Services segment, despite short-term profitability challenges [16][62] Other Important Information - SelectQuote has made significant progress on its capital structure, including a $100 million securitization and a $350 million strategic investment [31][32] - The company ended the quarter with an operating cash flow of $71 million and a cash balance of $86 million [32][33] Q&A Session Summary Question: Can you walk through the separation of growth in Medicare Advantage and SelectRx? - Management noted that while there was a decline in Medicare Advantage volume due to a smaller agent count, the efficiency of tenured agents helped drive strong performance in SelectRx [35][36] Question: What are the plans for agent growth in the upcoming season? - Management indicated that hiring is underway and they feel positive about the early stages of recruitment for the next season [40][42] Question: Can you discuss the impact of receivable securitization? - Management confirmed that they are exploring additional securitization options and have made progress on their capital structure [43][45] Question: How should investors think about MA LTV moving forward? - Management expects MA LTV to be down year-over-year in Q4 due to the shift in commission structure but will provide more details in the next earnings call [48] Question: What are the expected benefits from the new Kansas facility? - Management anticipates long-term benefits in operating efficiency and customer experience, although there will be a short-term drag on profitability [61][62]

Financial Data and Key Metrics Changes - The company's first quarter revenues were $696 million, down 5% year-over-year, and adjusted EBITDA was $58 million, down 18% year-over-year [4][5][15] - The decline in adjusted EBITDA was primarily due to intentional client exits and transformation-related investments [5][15] Business Line Data and Key Metrics Changes - In Branded Services, revenues were $257 million and adjusted EBITDA was $28 million, down 9% year-over-year [18] - Experiential Services generated $221 million in revenues and $12 million in adjusted EBITDA, down 12% year-over-year [19] - Retailer Services had revenues of $218 million and adjusted EBITDA of $18 million, down 3% and 7% year-over-year, respectively [19] Market Data and Key Metrics Changes - Consumer confidence declined, leading to lower consumer purchases and reevaluation of spending by clients [5][6] - Retailers experienced destocking trends, impacting overall order volumes [50][53] Company Strategy and Development Direction - The company is focused on modernizing its tech infrastructure and enhancing analytics capabilities to drive efficiency [11][12] - A task force has been mobilized to improve labor utilization and address staffing challenges [13][14] - The company is committed to being a cost-leading solutions partner to CPGs and retailers despite a softer growth environment [14] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a challenging labor market affecting event staffing and project execution [7][10] - Despite near-term challenges, the company remains optimistic about future performance and has a robust new business pipeline [6][7] - The revenue and adjusted EBITDA outlook has been lowered to flat to down low single digits due to macroeconomic factors [15][16] Other Important Information - The company ended the quarter with $121 million in cash and a net leverage ratio of approximately 4.4x adjusted EBITDA [20][26] - The ERP implementation is expected to yield greater cash flow benefits as systems are better utilized [25][26] Q&A Session Summary Question: Any notable changes in the macro environment? - Management noted improvements in hiring rates and smoother staffing challenges in Q2 compared to Q1 [32][33] Question: Have labor costs increased due to staffing issues? - Management indicated that labor cost inflation is in line with the macro market, and staffing issues were more related to talent acquisition strategies [39][40] Question: What is the impact of staffing shortages on EBITDA? - The majority of the decline in EBITDA was attributed to staffing shortages [68] Question: Is destocking continuing into Q2? - Destocking improved as Q1 progressed, but data for April was not yet available to confirm if it had completely stopped [70] Question: Breakdown of consumer products versus food companies? - Approximately 70% of the portfolio is in food, with strong presence in personal care and household goods [73]

Financial Data and Key Metrics Changes - The company reported a revenue of $15.2 million and an adjusted EBITDA loss of $1.2 million for Q1 2025, both showing a slight decline compared to Q4 2024 [11] - Total costs and expenses decreased by 25% year over year, amounting to over $6 million [11] - The company ended Q1 with $11.7 million in cash and cash equivalents and accounts receivable [13] Business Line Data and Key Metrics Changes - Revenue from services was $4.9 million, wellness was $9.2 million, and pet food and treats was $1.1 million in Q1 2025 [11] - Sales and marketing expenses were $10.4 million, which is within the historic range of 60% to 70% of revenue [12] Market Data and Key Metrics Changes - The company had 472,000 platform participants in the WAG ecosystem, reflecting a sequential quarter-over-quarter growth of 6% [11] Company Strategy and Development Direction - The company is focused on disciplined cost management and operational efficiencies, which have led to improved adjusted EBITDA despite a year-over-year decline in revenue [6] - Strategic partnerships with three major distribution partners are expected to enhance marketing positioning and drive growth in the insurance comparison business starting in Q2 [6][9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the momentum seen in early Q2 and emphasized a commitment to disciplined execution while growing efficiently [10] - The company remains focused on evaluating all strategic options to drive shareholder value [13] Other Important Information - The company is investing in AI and other technologies to optimize processes and systems, leading to increased efficiencies [12] - The board is evaluating potential options to improve the balance sheet and reduce debt [13] Q&A Session Summary - There were no questions during the Q&A session, and the call concluded without further inquiries [14]

Financial Data and Key Metrics Changes - Net sales for Q1 2025 were $322 million, compared to $316 million in the prior year period, indicating a slight increase [15] - Adjusted EBITDA for Q1 2025 was $25 million, with a margin of 15%, down from $31 million and 18% in the prior year [16] - The net loss for Q1 2025 was $13 million, which is a $20 million improvement compared to the same period last year [16] - Unlevered free cash flow increased to $33 million from $8 million in the prior year, driven by lower working capital [19] Business Line Data and Key Metrics Changes - Value-added sales decreased by approximately $3 million compared to the prior year, primarily due to lower unit sales and negative FX impact, partially offset by favorable pricing [16] - The adjusted EBITDA margin decreased due to unfavorable cost absorption from lower production volumes and metal timing [17] Market Data and Key Metrics Changes - The company experienced a significant increase in quoting activity, with over 53 million lifetime views year-to-date, double the level compared to the same time last year [5][11] - Tariff dynamics have created a favorable environment for localization in North America and Europe, with tariffs on Chinese imports exceeding 100% and Moroccan imports nearly 50% [10] Company Strategy and Development Direction - The company is focusing on securing short-term liquidity and is in discussions for a broader recapitalization transaction to deleverage the balance sheet [7][21] - The strategy includes enhancing the local manufacturing footprint in Mexico and Poland to capitalize on localization trends [5][11] - The company aims to position itself as a premier wheel solutions provider with a strong capital structure [7] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a challenging macroeconomic environment but highlighted the company's competitive advantages and opportunities arising from tariff pressures [4][5] - The company is suspending its full-year 2025 guidance due to uncertainties stemming from recent events and ongoing discussions with lenders [22] Other Important Information - The company has received a commitment letter from term loan lenders for up to $70 million in additional term loans, subject to certain conditions [21] - Total cash on the balance sheet as of March 31, 2025, was $54 million, with no amounts drawn on the $60 million revolving credit facility [20] Q&A Session Summary - There were no questions taken during the call, as management focused on providing updates and expressing gratitude for the team's efforts in a challenging environment [23]

Kaspi.kz (KSPI) Q1 2025 Earnings Call May 12, 2025 08:00 AM ET Company Participants David Ferguson - MD & Head of Investor RelationsMikheil Lomtadze - Chairman of the Management Board , CEO & DirectorYgal Arounian - Director - Internet Equity ResearchDarrin Peller - Managing DirectorReggie Smith - Executive Director - Equity Research Conference Call Participants Jamie Friedman - Senior FinTech and IT Services Research AnalystNone - AnalystGabor Kemeny - Senior Analyst Operator Hello, and welcome, everyone, ...

Kaspi.kz (KSPI) Q1 2025 Earnings Call May 12, 2025 08:00 AM ET Speaker0 Hello, and welcome, everyone, to the Kaspi KZ First Quarter twenty twenty five Financial Results. I will now hand you over to David Ferguson, Head of Investor Relations at Cassidy Cape Verde to begin. David, please go ahead. Speaker1 Great. Thank you, Maxine. Good afternoon, good morning to everyone. Thanks a lot for joining us for our first quarter twenty twenty five financial results. I'm David Ferguson. I'm joined, as usual, by Mikha ...